Cochrane Abstracts
Alemtuzumab for patients with chronic lymphocytic leukaemia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Alemtuzumab for Patients With Chronic Lymphocytic Leukaemia." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434436/1/Alemtuzumab_for_patients_with_chronic_lymphocytic_leukaemia.
Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434436/1/Alemtuzumab_for_patients_with_chronic_lymphocytic_leukaemia. Accessed September 21, 2025.
Alemtuzumab for patients with chronic lymphocytic leukaemia. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434436/1/Alemtuzumab_for_patients_with_chronic_lymphocytic_leukaemia
Alemtuzumab for Patients With Chronic Lymphocytic Leukaemia [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 September 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434436/1/Alemtuzumab_for_patients_with_chronic_lymphocytic_leukaemia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Alemtuzumab for patients with chronic lymphocytic leukaemia
ID - 434436
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434436/1/Alemtuzumab_for_patients_with_chronic_lymphocytic_leukaemia
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
